Figure 1a-d.

Dasatinib inhibits Src phosphorylation and downstream signaling. Cells were treated with varying concentrations of dasatinib for 1 day (a) or with 100 nM dasatinib for various durations (b). Equal amounts of protein were separated and subjected to Western blotting analysis with the indicated antibodies. U87 cells were treated with varying concentrations of dasatinib for 1 day (c) or treated with 100 nM dasatinib for the indicated durations (e). FAK, Lck and Lyn were immunoprecipitated (IP) and immunoblotted (WB) with the indicated antibodies as described in Materials and Methods